Boston Scientific’s Emerge™ PTCA Balloon Dilatation Catheter Cleared For U.S. Launch

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device in the United States. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary arteries. Both the Monorail® and Over-The-Wire (OTW) options are available. The Emerge Catheter has been commercially available in CE Mark countries since earlier this year.
PR Newswire (http://s.tt/1ov7B)

Pacemaker Donor Card Update

In a strikingly heartwarming example of humanity charities already exist to coordinate the distribution of usable, explanted pacemakers from deceased Americans to less fortunate people in the developing world. A new study suggests this is a safe and viable practice, although the manufacturers disagree, citing concerns over reprocessing practices.

St. Jude “Restructures” 300 Jobs Away, And Reshuffles Execs In Future-Proofing Move

St.Jude has taken the radical decision to shoe-horn its previous four divisions into two. These will be called the Implantable Electronic Systems Division (IESD), which will encompass CRM and Neuromodulation, and the Cardiovascular and Ablation Technologies Division (CATD), which will encompass Atrial Fibrillation and Cardiovascular. 300 job cuts and a host of efficiency savings are anticipated.